Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 109

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 109
---
 is mainly due to receipt of approval from EASME in April 2024.

Net cash used in operating
activities decreased by $0.3 million, to approximately $1.2 million for the year ended December 31, 2023 compared to net cash used in
operating activities of approximately $1.5 million for the year ended December 31, 2022. This decrease was mainly due to an increase in
our operating expenses which were offset by a decrease in our current assets.

Net cash used in investing activities

There were no net cash used
in investing activities during the six months period ended June 30, 2024 and 2023.

There were no net cash used
in investing activities during the years ended December 31, 2023 and 2022.

Net cash used in financing activities

Net cash used in financing
activities was and $0.17 million for the six months ended June 30, 2024 compared to none for the six month ended June 30, 2023. The
$0.17 million decrease was due to repayment net of short-term loans.

Net cash provided by financing
activities increased by $0.3 million, to approximately $0.3 million for the year ended December 31, 2023 compared to none for the year
ended December 31, 2022. This increase was due to proceeds from short-term loan and issuance of warrants.

Funding Requirements

We have incurred losses from
operations since the inception, resulting in an accumulated deficit on June 30, 2024 and December 31, 2023 of approximately $39.7 million
and $46.9 million, respectively. We anticipate that we will continue to incur net losses for the foreseeable future. We believe that our
existing cash and cash equivalents, without giving effect to the proceeds from this offering, will be sufficient to fund our projected
cash needs until March 2025. To meet future capital needs, we would need to raise additional capital through equity or debt financing
or other strategic transactions. However, any such financing may not be on favorable terms or even available to us. Our failure to obtain
sufficient funds on commercially acceptable terms when needed would have a material adverse effect on our business, results of operations
and financial condition. Our forecast of the period of time through which our financial resources will be adequate to support our operations
is a forward-looking statement that involves risks and uncertainties, and the actual amount of our expenses could